BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30515835)

  • 1. Pharmacological explorations of eco-friendly amide substituted (Z)-β-enaminones as anti-breast cancer drugs.
    Subramamiam P; Ramasubbu C; Athiramu S; Arumugam S; Alagumuthu M
    Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800244. PubMed ID: 30515835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
    Alagumuthu M; Arumugam S
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):389-397. PubMed ID: 28054203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-substituted hydroxynaphthalene imino-oxindole derivatives as new class of PI3-kinase inhibitor and breast cancer drug: Molecular validation and structure-activity relationship studies.
    Rajesh Kumar M; Alagumuthu M; Violet Dhayabaran V
    Chem Biol Drug Des; 2018 Jan; 91(1):277-284. PubMed ID: 28791774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
    Li ED; Lin Q; Meng YQ; Zhang LY; Song PP; Li N; Xin JC; Yang P; Bao CN; Zhang DQ; Zhang Y; Wang JK; Zhang QR; Liu HM
    Eur J Med Chem; 2019 Jun; 172():36-47. PubMed ID: 30939352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
    Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents.
    Amin KM; Eissa AA; Abou-Seri SM; Awadallah FM; Hassan GS
    Eur J Med Chem; 2013 Feb; 60():187-98. PubMed ID: 23291120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates.
    Khan I; Tantray MA; Hamid H; Sarwar Alam M; Sharma K; Kesharwani P
    Bioorg Chem; 2022 Feb; 119():105512. PubMed ID: 34861627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils.
    Bordoloi M; Saikia S; Kolita B; Sarmah R; Roy S; Narzary B
    Anticancer Agents Med Chem; 2018; 18(1):87-109. PubMed ID: 28356026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
    El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
    Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.
    Ebrahim HY; Mohyeldin MM; Hailat MM; El Sayed KA
    Bioorg Med Chem; 2016 Nov; 24(22):5748-5761. PubMed ID: 27681240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.